Clinical pharmacokinetics of dexketoprofen

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Pain Management

Background:

• Dexketoprofen is the S-(+)-enantiomer of ketoprofen, responsible for its analgesic and anti-inflammatory properties.
• Racemic ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis.
• Dexketoprofen trometamol is a water-soluble salt of dexketoprofen, enhancing its absorption and efficacy.

Purpose of the Study:

• To evaluate the pharmacokinetic and pharmacodynamic profile of dexketoprofen trometamol.
• To compare the efficacy and tolerability of dexketoprofen trometamol with racemic ketoprofen and placebo.
• To establish the optimal dosage and therapeutic window for dexketoprofen trometamol in pain management.

Main Methods:

• Pharmacokinetic studies measuring plasma concentrations and time to maximum concentration (tmax).
• Pharmacodynamic assessments including pain relief onset, duration, and intensity.
• Clinical trials comparing dexketoprofen trometamol to racemic ketoprofen and placebo in patients with moderate to severe pain.

Main Results:

• Dexketoprofen trometamol is rapidly absorbed, with a shorter tmax compared to racemic ketoprofen.
• The drug demonstrates significant analgesic efficacy superior to placebo, particularly at doses above 7mg.
• A dose-response relationship was observed, with 25mg showing extended duration of action, and the drug was well tolerated.

Conclusions:

• Dexketoprofen trometamol provides rapid and effective pain relief, with improved pharmacokinetic properties over racemic ketoprofen.
• The drug is well-tolerated and suitable for managing moderate to severe pain.
• Dexketoprofen trometamol represents a valuable therapeutic option in the NSAID class.